Evidence to Decision Framework

An evidence to decision (EtD) framework is a structured approach used in guideline development to move from evidence appraisal to actionable recommendations by explicitly considering multiple criteria beyond the research evidence itself. These criteria typically include the certainty of the evidence, the balance of benefits and harms, patient values and preferences, resource use (costs), health equity implications, acceptability to stakeholders, and feasibility of implementation. The EtD framework, developed by the GRADE Working Group, makes the reasoning behind recommendations transparent and reproducible.

Research evidence alone cannot determine what should be done. A treatment may have strong evidence of modest benefit but be prohibitively expensive. An intervention may be effective but unacceptable to the target population. A policy may improve average outcomes but worsen health disparities. The EtD framework is designed to make sure that all relevant considerations are explicitly addressed when translating evidence into recommendations, which helps keep guidelines connected to the realities of implementation. More than 120 organizations from over 20 countries, including WHO and Cochrane, have endorsed or are using GRADE, and guideline developers such as WHO use GRADE EtD frameworks to set out the reasoning behind their recommendations. Without a structured approach, guideline panels may be unduly influenced by the most vocal members, may overlook important considerations, or may produce recommendations whose reasoning is opaque to users.

The EtD framework is applied after the evidence has been synthesized and its certainty assessed using the GRADE approach. The guideline panel works through a series of structured questions, each addressing a criterion relevant to the recommendation.

The panel usually begins by asking whether the problem is a priority, then turns to the evidence: how large are the desirable and undesirable effects, how certain are we about them, and what is the balance between them? The panel considers not only the magnitude of benefits and harms but also their relative importance from the patient's perspective. Some outcomes (such as avoiding a catastrophic side effect) may be weighted more heavily than others (such as a modest improvement in a symptom score).

The next set of questions addresses values and preferences: how much do patients value the outcomes? is there important variability in how patients value the outcomes? If patients strongly and uniformly value the outcomes, the recommendation can be stronger; if there is substantial variability, a conditional recommendation may be more appropriate.

Resource use is considered through questions about the costs of the intervention, the cost effectiveness evidence, and whether the intervention represents a reasonable use of resources. Equity considerations ask whether the intervention would reduce or increase health disparities. Acceptability questions address whether stakeholders (patients, clinicians, policymakers) would find the intervention acceptable. Feasibility questions ask whether the intervention can be implemented in the relevant settings.

After working through all criteria, the panel formulates a recommendation, specifying its direction (for or against the intervention) and its strength (strong or conditional/weak). A strong recommendation reflects confidence that the desirable consequences clearly outweigh the undesirable ones (or vice versa), so that most informed patients would choose the recommended course of action and only a small proportion would not. A conditional recommendation reflects uncertainty about the balance of consequences, variability in patient values, or dependence on specific circumstances.

The EtD framework should be used whenever a guideline panel is developing clinical, public health, or policy recommendations based on evidence. It is appropriate for treatment recommendations, screening recommendations, diagnostic recommendations, and public health interventions. It is most valuable when the evidence is uncertain, when the balance of benefits and harms is close, when costs or feasibility considerations are important, or when the recommendation may have equity implications. It is not necessary for purely scientific conclusions (such as the results of a systematic review) that do not involve a recommendation for action.

A common error is using the EtD framework as a checklist rather than a deliberative process, going through the motions without genuine panel discussion and reflection on each criterion. Another mistake is allowing one criterion (such as the strength of the evidence) to dominate the deliberation without giving adequate weight to other important criteria like equity, feasibility, and patient values. Guideline panels sometimes fail to include relevant stakeholders (patients, frontline clinicians, policymakers) in the deliberation, producing recommendations that do not reflect the perspectives of those most affected. Conflating the strength of the recommendation with the certainty of the evidence is another common error; strong recommendations can sometimes be made on the basis of low certainty evidence when the consequences of inaction are severe. Finally, failing to document the EtD deliberation transparently reduces the credibility of the recommendation and prevents users from understanding and applying the panel's reasoning.

A guideline panel uses the EtD framework to develop a recommendation on routine iron supplementation for pregnant women in low income countries (a hypothetical example; its figures are illustrative). The evidence synthesis shows moderate certainty evidence that supplementation reduces anemia (RR 0.50, 95% CI: 0.42 to 0.59) and low birth weight (RR 0.81, 95% CI: 0.71 to 0.93). The panel rates the balance of benefits and harms as favoring supplementation (benefits are large, side effects are minor). Patient values assessment shows that pregnant women strongly value preventing anemia. Resource use analysis shows that iron supplements cost approximately $3 per pregnancy. Equity assessment indicates that supplementation would disproportionately benefit disadvantaged populations with higher anemia rates. Feasibility assessment confirms that antenatal care platforms exist to deliver supplementation. The panel issues a strong recommendation for routine iron supplementation, documented with the full EtD rationale.